|
|
|
Czech Centre for Phenogenomics
|
|
|
|
|
From Vision to Excellence - Celebrating 10 years of CCP
|
|
|
|
The Czech Centre for Phenogenomics marks its tenth anniversary as a leading national and European infrastructure for disease modelling and phenotyping, having grown from a small transgenic unit into one of Europe’s most comprehensive centres. With over 140 experts and an integrated pipeline spanning genome editing, high-throughput phenotyping, and preclinical testing, CCP serves as a “one-stop shop” for academic and industrial users and plays a key role in international initiatives such as INFRAFRONTIER and the International Mouse Phenotyping Consortium. By combining state-of-the-art in vivo technologies with forward-looking investments in rare disease research, gene therapy, advanced in vitro models, and AI-driven phenotyping, CCP stands as a mature, internationally recognised hub committed to innovation and scientific excellence for the benefit of society.
|
|
|
|
RD - Factory: Accelerating Solutions for Rare diseases from the Lab to the Clinic
|
|
|
|
The RD-Factory at the Czech Centre for Phenogenomics, is a strategic, patient-oriented initiative that accelerates the translation of genetic discoveries into clinically relevant solutions for rare diseases. By integrating advanced genome engineering, disease-specific models, deep phenotyping, and translational expertise. Supported by close collaboration with the Institute of Molecular and Translational Medicine (IMTM), the program functions as a “one-stop shop” linking gene discovery directly to preclinical development. With an open nomination system, regulatory-grade environments, and a growing portfolio of high-priority rare disease projects, RD-Factory serves as a powerful engine for moving promising therapies efficiently from the laboratory to the clinic for the benefit of patients and society. read more
|
|
|
|
Transforming Insights: A Decade of Phenotyping Excellence at CCP
|
|
|
|
Over the past decade, phenotyping at the Czech Centre for Phenogenomics has evolved from standardized assays into a mature, integrated research ecosystem linking gene discovery, disease
mechanisms, and preclinical translation. With more than 600 genes phenotyped and over 1,000 physiological parameters measured, phenotyping has become a central intellectual driver of CCP’s research, supporting advanced disease models, rapid responses to societal challenges, and GLP-compliant preclinical studies that have enabled clinical trials.
|
|
|
|
Through tight integration of technology, data analysis, and biological insight, CCP now transforms complex phenotypic data into actionable knowledge with tangible impact on medicine and society. read more
|
|
|
|
A Decade of High-Impact Science: CCP´s Contribution to the World´s Leading Journals
|
|
|
|
While CCP is renowned for its service to the user community, its scientific footprint is perhaps best measured by the calibre of publications its team has co-authored. From unravelling the fundamental "dark matter" of the genome to responding to global pandemics, CCP researchers have consistently published in the world’s most prestigious journals, including Nature, Cell, and Nature Genetics. Key contributions include the 2016 Nature study revealing that nearly one third of gene knockouts are embryonically lethal, the 2017 Nature Communications paper demonstrating widespread sexual dimorphism in gene phenotypes, and Nature Genetics papers on eye development, metabolic regulation, and a 2021 IMPC flagship resource of mutant mouse lines for 5,061 genes. Subsequent studies (Nature Communications 2022, Scientific Reports 2024) analysed genome-wide knockouts to identify candidate disease genes and assess gene essentiality in large-scale genome editing. CCP has also delivered mechanistic and translational insights, including a 2023 Nature study linking APS-1 genetic defects to tooth enamel pathology, a 2021 Nature COVID-19 study testing bispecific antibodies in humanized mouse models, and the 2024 Nature Communications LAG-R guidelines establishing global standards for reporting animal genetic engineering. Collectively, these publications underscore CCP’s dual role in advancing fundamental biology and driving clinically relevant biomedical research .
|
|
|
|
|
|
Bridging the Gap between Genes and Therapy: Highlights from the 2025 CCP Phenogenomic Conference
|
|
|
|
The 7th CCP Phenogenomics Conference, held in Prague on September 11–12, 2025, brought together an international community of scientists and clinicians to highlight advances in rare disease research, experimental models, and gene therapy, with a strong emphasis on translation from gene discovery to therapy.
|
|
|
|
|
Under the theme “For Users, With Users,” the meeting reinforced CCP’s role as a collaborative hub and featured keynote lectures from leading experts, including Gary Peltz on computational and humanized mouse models, Frank Buchholz on precision genome surgery, Yann Herault on advanced disease modelling, and Timothy W. Yu on individualized gene-targeted therapies. Alongside focused discussions on rare disease mechanisms and therapeutic innovation, the conference showcased initiatives such as the RD-Factory and underscored how integrated phenotyping, genome engineering, and translational expertise are accelerating the path from genetic insight to clinical impact. read more
|
|
|
|
|
|
SAVE THE DATE: Announcing the 8th CCP Phenogenomics Conference 2026
|
|
|
|
|
|
CCP announces the 8th Phenogenomic Conference, to be held in Prague on September 9 - 11, 2026. Building on the success of the 2025 meeting, the conference will focus on key advances in rare genetic diseases, experimental disease models, and gene therapy, offering a leading platform for international collaboration and the translation of genetic discoveries into clinical solutions. read more
|
|
Czech Centre for Phenogenomics
|
Institute of Molecular Genetics of the
Czech Academy of Sciences
|
|
|
|
|
|
